Hi everybody. One of the most amazing things that's happened over the last year or so is the explosive growth of weight reduction medicines.

Nova Nordisk, one of the world leaders, is just incredibly interesting, and we have therefore decided to rerun the interview we had with the CEO.

We are back on the 7th of August. We'll add total new lineup for the autumn. You will be amazed.

Tune in.

So, Lars, very welcome to the podcast. Nova Nordisk has got an unrivaled reputation worldwide, so it's fantastic to have you on.

Thank you, Nibla.

It's in order to be here.

Now, I thought I'd kick off on obesity because it's such a big problem.

And it's triples in 75, more than 1 billion people are obese.

And I read somewhere that it now accounts for nearly the cost of obesity

nearly accounts for 3% of world GDP. Now, what are the drivers behind this?

It's interesting to reflect on obesity and the fact that it's now being recognized as a disease,

not among all, but increasingly.

And until now, there has not been real efficacious medicine.

And when you don't have efficacious medicine, often the medical community is not highly

engaged in a disease.

So what's happening now is that we acknowledge that it's not just about lifestyle.

It's not just about how much we eat.

It's actually about genetics, that different people are in different situations

from a physiology point of view.

And it really takes help for those people.

So that's what's now opening up the whole market.

...